Compare Aventis Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs GLENMARK PHARMA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA GLENMARK PHARMA SANOFI INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 35.1 12.5 281.2% View Chart
P/BV x 6.2 1.8 344.6% View Chart
Dividend Yield % 1.4 0.5 261.3%  

Financials

 SANOFI INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
GLENMARK PHARMA
Mar-19
SANOFI INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs6,840712 961.2%   
Low Rs4,630484 957.4%   
Sales per share (Unadj.) Rs1,203.1349.6 344.1%  
Earnings per share (Unadj.) Rs165.332.8 504.1%  
Cash flow per share (Unadj.) Rs209.944.3 473.4%  
Dividends per share (Unadj.) Rs84.002.00 4,200.0%  
Dividend yield (eoy) %1.50.3 437.6%  
Book value per share (Unadj.) Rs963.6198.6 485.1%  
Shares outstanding (eoy) m23.03282.17 8.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.81.7 278.9%   
Avg P/E ratio x34.718.2 190.4%  
P/CF ratio (eoy) x27.313.5 202.7%  
Price / Book Value ratio x6.03.0 197.8%  
Dividend payout %50.86.1 833.1%   
Avg Mkt Cap Rs m132,078168,625 78.3%   
No. of employees `0003.312.0 27.4%   
Total wages/salary Rs m4,06820,561 19.8%   
Avg. sales/employee Rs Th8,393.88,196.0 102.4%   
Avg. wages/employee Rs Th1,232.41,708.1 72.1%   
Avg. net profit/employee Rs Th1,153.0768.5 150.0%   
INCOME DATA
Net Sales Rs m27,70898,655 28.1%  
Other income Rs m8972,081 43.1%   
Total revenues Rs m28,605100,736 28.4%   
Gross profit Rs m6,23515,858 39.3%  
Depreciation Rs m1,0273,259 31.5%   
Interest Rs m73,346 0.2%   
Profit before tax Rs m6,09811,335 53.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m2,2923,756 61.0%   
Profit after tax Rs m3,8069,250 41.1%  
Gross profit margin %22.516.1 140.0%  
Effective tax rate %37.633.1 113.4%   
Net profit margin %13.79.4 146.5%  
BALANCE SHEET DATA
Current assets Rs m15,92266,968 23.8%   
Current liabilities Rs m6,23540,211 15.5%   
Net working cap to sales %35.027.1 128.9%  
Current ratio x2.61.7 153.3%  
Inventory Days Days6483 76.4%  
Debtors Days Days2181 25.7%  
Net fixed assets Rs m7,53933,322 22.6%   
Share capital Rs m230282 81.5%   
"Free" reserves Rs m21,96255,770 39.4%   
Net worth Rs m22,19256,052 39.6%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m29,839132,888 22.5%  
Interest coverage x872.14.4 19,877.5%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.7 125.1%   
Return on assets %12.89.5 134.8%  
Return on equity %17.216.5 103.9%  
Return on capital %27.517.8 154.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58762,998 12.0%   
Fx outflow Rs m7,14522,859 31.3%   
Net fx Rs m44240,140 1.1%   
CASH FLOW
From Operations Rs m3,73913,242 28.2%  
From Investments Rs m-731-6,990 10.5%  
From Financial Activity Rs m-1,972-7,387 26.7%  
Net Cashflow Rs m1,036-2,971 -34.9%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 6.9 208.7%  
FIIs % 14.6 34.4 42.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.5 100.0%  
Shareholders   15,184 56,727 26.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 13, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS